

INVESTOR PRESENTATION

GPI

AUGUST 2020

The context Healthcare



HEALTHCARE: A PIVOTAL MARKET

A segment that can impact a country's economic development, the keeping of public accounts and its very social cohesion



AN EVOLVING MARKET

- demographic ageing and increased life expectancy
- increased **health costs** (chronic)
- **shortage** of healthcare staff (doctors) and resources



2019 ITALY HEALTHCARE EXPENDITURE

115 B €

20% waste and inefficiency

INCREASED DEMAND FOR CARE



THE CHALLENGE: to make the health systems sustainable, limiting spending and improving quality of service



OPPORTUNITIES:

ORGANISATIONAL and TECHNOLOGICAL RENEWAL (digital health care)

Rethinking the organisational models and processes used by the health authorities



Your Global Partner for a Better Future

We develop software, technologies and services to help the health care providers to innovate the models of care, assistance and prevention, optimizing processes and containing costs.

A partnership to make health systems sustainable and help improve people's health and well-being.





Strategic Business Areas

TECHNOLOGIES 50.6%



Note: % revenues for SBA out of total revenues referring to FY 2018



Supply Lines



main SBAs

87.5% of total revenue



Software

hospital information system

- health social care
- blood transfusion & tissue bank
- health administration
- data analytics
- other



Care

- BPO health care administrative svc. (AtC,...)
- telemedicine
- other



- automated pharmacy warehouse
- automated hospital pharmacy supply chain

other SBAs

12.5 % of total revenue



HW & SW on-site / on-line maintenance and aassistance






- e-payment and e-mandate solutions
- electronic storage




GPI in figures




Net profit €M



EBITDA €M *





A history of steady growth

- 2013 Orizzonte fund providing equity financing - First minibond issued.
- 2016 merger between GPI and the SPAC CFP1.
 Start of trading in the stock market AIM Italia.
- **2018** graduated from AIM to MTA main market of Borsa Italiana.
- > **75 mln M&A** deals



^{*2017} and 2018 EBITDA, net of extraordinary costs; 2019 EBITDA includes the effects of IFRS 16

Gpi vs Covid-19

- Permanent activity supporting the NHS also during the lockdown
- **Immediate activation** of **actions to protect** the health of employees, collaborators, suppliers, partners and customers
- Reporting a **slowdown** of the *ordinary health care activities* and an **increase** of *extraordinary activities*
- Orders confirmed + increased demand for innovative solutions e.g.:

CONTACT CENTRE 24/7
INFORMATION SERVICES
ON COVID-19



WEB SOLUTIONS, APPS
AND SERVICES TO
REGULATE ACCESS TO
PHARMACIES,
SUPERMARKETS AND SAMPLE CENTRES

SCREENING SW SOLUTIONS
TO MANAGE THE MASS USE
OF NASOPHARYNGEAL
SWABS



APP FOR NAVIGATION
INSIDE THE HEALTH CARE
FACILITIES



TELEMEDICINE: INTEGRATED ECOSYSTEM OF SOFTWARE SOLUTIONS, MOBILE and WEARABLE DEVICES, OPERATIONS CENTRE SERVICES FOR THE TECHNOLOGY RELATED ASSISTANCE, THE MONITORING OF CLINICAL PARAMETERS AND THE HOME CARE FOR PATIENTS














Segmentation



^{*} H-pub: public healthcare customers; H-Pri: private healthcare customers, NH-Pub: public non-healthcare customers; NH-Pri: private non-healthcare customers





Focus on SBA software

Adj. revenue €M

EBITDA €M

Supply lines






HR

■ Blood Bank

Other





Tenders win ratio**

• 35%

Revenue predictivity

• 50%

Customer retention

• 92%

Average contract term

• 1-3 years

Average value of tenders acquired

• 6-7 mln/€ year

Competitive position


• 3rd player IT




^{**}Win Ratio as a % of wins to n° of bids.
Conversion Win Ratio 6.8% (won contracts value to tenders value 2017-2019)

Focus on SBA Care

Adj. revenue €M EBITDA €M Δ+30%





Supply lines



Tenders win ratio**

• 40%

Revenue predictivity

• 95%

Customer retention

97%

Average contract term

4-6 years

Average value of tenders acquired

• 10-15 mln/€ year Competitive position


• 1st operator IT





^{* 2018} EBITDA adjusted by extraordinary costs for listing on the MTA


^{**} Win Ratio as a % of wins to n° of bids.
Conversion Win Ratio 16.4% (won contracts value to tenders value 2017-2019)

Focus on other SBAs ♥ ♥ 〒









Automation



Sales of HW for automated warehouses (approx. 87%) and maintenance and service fees (approx. 13%)

- Retail Italy approx. 64%
- Hospital Italy approx. 16%;
- International Hospital & Retail approx. 20%

ICT



Desktop management services fees (approx. 89%) other system services (approx. 11%)

- Healthcare customers approx. 77%
- Non-healthcare PA approx. 17%
- Other private customers approx. 6%

PAY



ePayment services (approx. 85%), income from 🔽 POS rental and related software (approx. 15%)

- Organised distribution approx. 50%;
- PAL approx. 23%
- Suppliers of POS-based services approx. 17%
- System integrator approx. 10%




24.8

2018

2019


The customers

+2,200
Public and private customers





• GPI worldwide



ITALY

> 40 branches

SOLUTIONS WORLDWIDE

> 60 countries



Overview and main results FY2019

Highlights

- Region of Lazio contract start up 18 lots and Regional Contact Centre:
 €72 M in 2 years + 1-year extension (Care: CUP)
 6 million more citizens reached
- Award of tender for the Region of Veneto: €79 M in 5 + 2 years €27.5 M GPI share (Software: SIO) 8 thousand beds
- Award of 4 tenders in the Region of Marche:
 €4 M GPI share (Software: FSE, CUP, SISTE, DOC)
 5 thousand beds
- Issue of €30 M debenture several underwriters, supported by Cassa Depositi e Prestiti (Deposits and Loans Fund) as anchor invest

M&As

- Haemonetics (assets): U.S. global company listed on the NYSE (Blood Bank) | 11,3 M \$ Rev. |35% EBITDA | 100 clients USA (May 2020)
- Medinfo Group: 3 companies France, Tunisia, Chile (Blood Bank) | 3,9 M€ Rev. | 33% EBITDA | 60 clients NHS UK, Army France and Belgium (May 2020)
- Oslo (Management Reporting System, Big Data & Analytics) | 4,3 M€ Rev. | 30,2% EBITDA (April 2020)
- Guyot Walser Informatique (Blood Bank)
 360 healthcare facilities in France (Nov. 2019)
- Accura (Chronic patient management) and Business
 Process Engineering (Data Protection) In Italy

Export + 16.4%: new orders Pharmacy

Warehouse Automation (> €2 M): Austria, China, Qatar, Saudi Arabia, Switzerland, Hungary, Ireland



Significant growth in 2019

Revenues +18.3%, Net profit +3.1%

Revenue €240.9 M, **+18.3%** thanks to the contribution made by the SBAs:

- Care **+35.0%**
- Other **+21.2**%
- SW **+1.2**%

2019 characterised by

- 3 acquisitions
- 2 NewCos
- Incorporation of 1 subsidiary

EBITDA: €32.2 M, 14.4% of adj. revenue

Net profit: €9.8 M +3.1%

€M	2019	2018
Revenue and other income	240.9	203.7
Adj. revenue (1)	223.3	192.9
EBITDA	32.2	28.6 ⁽²⁾
EBITDA % of adj. revenue	14.4%	14.8%
Pre-tax profit	12.8	12.8
Net profit (loss)	9.8	9.5



⁽¹⁾ Net of Temporary grouping of companies (RTI)

⁽²⁾ Net of extraordinary costs for listing on the MTA

2019 financial highlights

A3.1 CERVED Rating confirmed A- S&P | A3 Moody's | A-1 Fitch

Net working capital

€91.3 M (€75.6 M in 2018):

- increase due to growth in revenues and the acquisition of significant orders at year end; accordingly, trade payables also rise (€37.8 M vs €32.2 M)
- product warehouse: increase connected above all with SBA Automation (€4.8 M vs €3.9 M)

Shareholders' equity

€72.1 M (€68.6 M in 2018):

- 2018 dividend payment
- FY 2019 profit
- purchase of treasury shares

Net financial position

€82.8 M (€69.2 M in 2018 - including the effect of IFRS 16)

Investments: M&As €1.8 M | R&D €7.1 M

€M	2019	2018
Net working capital	91.3	75.6
Non-current assets	119.4 (1)	105.2
Other operating assets/(liabilities)	(55.8)	(50.7)
NET INVESTED CAPITAL	154.9	130.1
Shareholders' equity	72.1	68.6
Net financial position	82.8	61.5 (2)
TOTAL SOURCES	154.9	130.1

⁽¹⁾ Includes €11.8 M due to the IFRS 16 effect



⁽²⁾ Net of €7.7 M due to the IFRS 16 effect

Target market and competitive environment

Market Analysis Software

Market value

\$60 bn



value of the global **2018 Healthcare IT software + services market**

47 % North America	CAGR 18 – 22: 6.1%
28 % Western Europe	CAGR 18 – 22: 5.4%
10% Mature Asia/Pacific	CAGR 18 – 22: 4.3%
5 % Latin America	CAGR 18 – 22: 5.3%
1 % Greater China	CAGR 18 - 22: 13 3%

\$0.8 bn*



value of the Italian 2018 Healthcare IT software + services market

1.4% of the global market CAGR 18 – 22: **3.5**%

€1.7 bn HealthCare IT market

€1.1 bn HealthCare IT software + services market




|| Source: Gartner (2019)

|| Source: Netics (2019)

Market Analysis Software

Top market players

Company	Brief description	Focus on healthcare	Ranking
Dedalus idunicate syrus prouv	ICT solutions and related services for public and private healthcare providers.	✓	1st
ENGINEERING	ICT solutions for the segments: finance, industry, telco&utilities and PA .	Through dedicated healthcare division	2nd
Gpi	ICT solutions, administrative and social-healthcare services for public and private healthcare providers.	√	3rd
	Software for hospital processes, orders and risk management Group reply part.	✓	4th
exprivia	Digital transformation & ICT services for industries, energy, aerospace, healthcare , PA, etc.	Through dedicated healthcare division	5th





Market Analysis Care Market value & players





global market value of administrative services not available because of its heterogeneous nature - international comparison impossible.





Italian market value of administrative services (2017)

value underestimated insofar as, at present, part of the market is still insourced.

> 28 M citizens reached

Company	Brief description	Ranking
Gpi	ICT solutions, administrative and social-healthcare services for public and private healthcare providers.	1st
ALTHEA	Maintenance services for medical devices, operative in 17 different countries.	N/A
Copservice	BPO services (e.g. cleaning, security, logistics and healthcare services).	N/A
Cooperation Sociale ANTHESYS SERVIZE	Local supplier of services for healthcare and the educational segment, operates in the Region of Veneto.	N/A
D A R C O	Local supplier of services for healthcare, operates in the Region of Lazio.	N/A





Strategic intentions 2020-2024

Strategic-corporate intentions 2020 - 2024



01

02

03

04

05

EVER MORE GLOBAL

GROWTH IN PRIVATE HEALTH CARE

ITALY
HEALTH CARE
SW MARKET
LEADERSHIP

from
PRODUCTS/
SERVICES to
INTEGRATED
SOLUTIONS

from
PROVIDER to
PARTNER

Strong increase over the BP period

Geographical areas of growth: DACH, Russia, China, Middle

East and

America

doubling up of the segment % weight

Major regional and national tenders

M&As

Focus of R&D on Machine
Learning and on the digital transformation

Greater integration of services | SW | technologies to respond to the evolution of healthcare models and the healthcare demand.

Multi-business nature with the contribution of all SBAs.



Strategic intentions SBA

MARKET POSITIONING consolidation of the market position (up-selling and cross-selling), continuous participation in major tenders and strategic partnerships.

GLOBALISATION/TARGET SHIFTING increase in the percentage share of turnover for the ASA referring to international customers: the target value is 20%.

PRODUCTS PORTFOLIO
harmonisation of the products portfolio,
review of the production process to increase productivity and product quality,
innovation and technological evolution of the platforms.

Software

>_

DEVELOPMENT DRIVERS

- Average retention ('17-'19)91%
- Revenue predictivity50%
- Up/cross selling2.5%
- Tenders/year€6-7 M





Strategic intentions SBA

Care



CONSOLIDATION OF THE COMPETITIVE POSITIONING consolidate the market share on the H-PUB target on

consolidate the market share on the H-PUB target on a national level and the current territorial presence (approx. 50% of the domestic market) through:

- continuous participation in important tenders,
- direct contract acquisition,
- extension of the supply contracts stipulated.
- DEVELOPMENT OF THE PRIVATE HEALTHCARE MARKET develop, define and market the portfolio of new services towards the private H-PRI target group (private clinics, COT, nursing homes, etc.) and to manage chronic patients.
- 103. INFRASTRUCTURAL EVOLUTION technologically evolve the infrastructure in support of services to foster a multichannel approach in access (voice systems, apps, social engagement) and introduce artificial intelligence algorithms to automate certain reception services and reduce the operator's workload.
- TECHNOLOGICAL AND PROCESS EVOLUTION increase efficiency in the supply of contact centre services through the introduction of a technological platform to support HR planning and programming.

DEVELOPMENT DRIVERS

- Average retention '17-1997%
- Revenue predictivity range98%-45%
- Tenders/year€10-15M





Strategic intentions Other SBAs

AUTOMATION

PRODUCT AND VALUE PROPOSITION INNOVATION THROUGH R&D OPERATIONS develop new technological solutions (e.g. automated basket/cabinet system for medical devices/cart kit engineering, etc.) and enter new segments (e.g. evolved self-service type solutions and vending machines for the pharmaceutical area, etc.).

RETAIL MARKET DEVELOPMENT

enter the market of the major pharmacy chains (capital companies) both for automation and furnishing. Cross-selling of the Warehouses and Pharmacy Design Studio range.

ICT

STRATEGIC PARTNERSHIPS FOR NATIONAL TENDERS

development of strategic partnerships with the market's big players (TIM, FastWeb, etc.)

INNOVATION OF OFFER ON PRIVACY & CYBER SECURITY new value proposition focussed on privacy & cyber security on PAL target and healthcare

PAY

DEVELOPMENT OF THE PUBLIC ADMINISTRATION MARKET

payment services/electronic collection and replacement storage services for the PA DEVELOPMENT OF SMART PAYMENT FOR VENDING MACHINES

R&D on this topic, partnering dispenser manufacturers and alternative-micro payment systems (e.g. Tinaba, ALIpay, etc.).

DEVELOPMENT OF THE ORGANISED CATERING SEGMENT improvement of the competitive positioning

DEVELOPMENT DRIVERS

AUTOMATION



- Italy retail (H-PRI, NH-PRI)
- Italy hospital (H-PRI, H-PUB)
- International through Riedl
- International through GPI network

ICT



- Order backlog
- Extension of contracts
- New contracts

PAY




- Large retail and PA (recurring)
- New services PA
- New services Large retail
- Vending machines



2024 economic-financial targets

Equal scope of consolidation as of 31/12/2019








2024 Revenue and EBITDA without M&As

ASA breakdown, equal scope of consolidation as of 31/12/2019







M&A Guidelines

Historic M&A process

ACQUIRED
Spid (16%)
Selfin (health)
INCREASED HOLDING IN

Sysline (70%)

ESTABLISHED

MADO

CRG

ACQUIRED

Sintac (23%)

CONSOLIDATED

Selfin.it (100%) S.O.I.V.E. (100%) Hit (100%) Skyline (100%)

ESTABLISHED

GCS (51%) Ziti Tecnologia Ltda GPI Africa Austral Sa ACQUIRED

Evolvo GPI (80%) Lombardia Contact (100%) GPI Technology (80%) GPI Chile (51%) Saluris (19%) ACQUIRED

Saluris (60%) DO.MI.NO (70%)

Nuova Sigma (100%)

EDP Sistemi (100%) Net Medica (100%)

Info Line (100%)

Xidera (60%)

Hemasoft (60%)

Hemasoft America (60%)

BIM Italia (70%)

CONSOLIDATED

CRG (100%) SPID (100%)

GSI (100%)

Evolvo GPI (100%) GPI do Brasil (100%)

JOINTLY HELD

Safeaty (19,9%) UpSens (5,4%) ACQUIRED

Accura (80%)
Business Process Enginering (71,6%)
Guyot Walser Informatique (60%)

CONSOLIDATED

Uni IT

ESTABLISHED

Healthech PeopleNav

1988-

GPI established in October 2011

2012

2013

_

2014

2015

2016

2017

2018

2019

2020

ACOUIRED & CONSOLIDATED

Logicast (100%) Larca (100%) Argentea (100%)

ACQUIRED Sysline(65%)

Selfin.it

2010

ESTABLISHED

ACQUIRED

GCS (health)

INCREASED HOLDING IN

Spid (78%) Sysline (90%) Hit (90%)

ESTABLISHED

Consorzio SST (8%) Argentea (80%) Neocogita (24%) ACQUIRED

Riedl (51%) Sferacarta GPI (51%)

INCREASED HOLDING IN

GSI (51%) GCS (75%) Sintac (51%) Spid (80,8%)

ESTABLISHED

GPI Middle East (Abu Dhabi)

ACQUIRED

GPI Technology (100%) Sferacarta GPI (100%) GCS (100%)

Gbim (70%)

Innovazione e Tecnologie (health) Insiel Mercato (55%)

PCS (100%)

ESTABLISHED

Groowe Tech

ACQUIRED

Paros (100%) Unit IT (100%) Erre Effe (100%)

INCREASED HOLDING IN

Insiel Mercato (100%) Neocare (100%)

Groowe Tech (100%)

ESTABLISHED

Argentea (Poland) (65,60%) Informatica Group (Russia) (100%) Cliniche della Basilicata (67%)

CONSOLIDATED

Edp
Erre Effe Informatica
Groowe Tech
Neocare
Insiel Mercato
Infoline
Net Medica
Nuova Sigma

Paros

ACOUIRED

Oslo (65%) Haemonetics (assets)

INCREASED HOLDING IN


Business Process Engineering (100%) TBS IT (100%) BIM Italia (100%)

CONSOLIDATED

Business Process Engineering Sintac TBS IT




M&A Guidelines





M&A Guidelines



RESOURCES

- BONDS
- TRADITIONAL FINANCING
- WARRANTS
- SHARES/SHARES
 - Big players
 - Abroad



Investment Attractiveness

Leadership and Uniqueness

Growth and Visibility

Technology and Service

Evolution of market/client

M&A Opportunities

GPI IN THE STOCK MARKET

Bloomberg: GPI:IM

15,909,539 Ordinary Shares (ISIN: IT0005221517)


Price: 6.68 € (3 August 2020)

Capitalisation: 106.3 M€ (3 August 2020)

ANALYST COVERAGE – Target price

Intermonte SIM (22/04/2020): 10,00 € Banca Akros (02/04/2020): 11.00 €

SHAREHOLDING STRUCTURE



IR Contact details



Fabrizio Redavid Mob. +39 335 1035499 fabrizio.redavid@gpi.it Lorenzo Giollo Mob. +39 340 8223333 lorenzo.giollo@gpi.it

Via Ragazzi del '99, 13 - 38123 Trento T +39 0461 381515 investor. relations@gpi.it



Maria Antonietta Pireddu

Via C. Cantù, 1 - 20123 Milan Tel. +39 02 45473883/4 m.pireddu@irtop.com



Disclaimer

The material in this presentation was prepared by GPI S.p.A. ("GPI" or the "Company") without any form of independent verification; it is general, basic information about the current business of GPI as at the date of this presentation. This information is supplied in summary form and is not complete. This presentation is provided for information only and is not an offer or solicitation of an offer of purchase or sale of securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such an offer, solicitation or sale should be illegal before the registration or qualification in accordance with the laws on securities of that jurisdiction. It is intended exclusively by way of a presentation to investors and is provided for information only. This presentation does not contain all information that may be relevant to an investor.

The information contained in this presentation, including the forecast financial information, must not be considered as advice or recommendations to investors or potential investors in connection with the holding, purchase or sale of securities or other products or financial instruments and does not take into account any specific investment targets nor the financial position. Before acting, it is important to consider the adequacy of information in relation to such subjects and, in particular, independent financial advice should be taken. All securities and product transactions or financial instruments entail risks, which include, amongst others, the risk of adverse or unforeseen market, financial or political developments and, in international transactions, the foreign exchange risk. The information contained in this presentation is confidential and is supplied to the user for information only and cannot be reproduced, re-sent or further distributed to anyone else, nor published, entirely or partly, for any purpose. This presentation is only distributed to and intended for: (A) persons in the European Economic Area Member States (excluding the United Kingdom), who are classed as "qualified investors" under Article 2, paragraph 1, letter e) of Directive 2003/71/EC (as amended and complete with any implementing measures applicable in each Member State); (B) in the United Kingdom, professional investment qualified investors coming under Article 19 (5) of the 2005 Order (financial promotion), the Order of Financial Services and markets and/or companies with high shareholders' equity and other persons to whom it can be lawfully disclosed, pursuant to Article 49,

paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be legally distributed and disclosed in accordance with applicable laws (all those pursuant to points (A) to (C) above, indicated as "relevant persons").

The information contained in this presentation may include forecasts. Although the Company believes it has a reasonable basis on which to make the forecasts given in this presentation, GPI warns that forecasts are no guarantee of future performance and that the effective operating results, financial conditions and conditions of liquidity and development of the segment in which GPI operates may differ considerably from those effectively achieved or suggested by the declarations given in this presentation or made by the GPI management team. Past performance is also not a reliable indication of future performance.

GPI makes no promise to update or publicly review the forecasts, even if new information is revealed or for any other reason. The information and opinions given in this presentation or in the declarations made by the GPI management team are given as at the date of this presentation or any other date, if indicated, and are subject to change without notice. Do not rely on the information given in this presentation for any purpose. No express or implicit declaration or guarantee is given by GPI, its subsidiaries or the respective consultants, functionaries, employees and agents, as regards the accuracy of information or opinions or for any loss as may derive directly or indirectly from any use of this presentation or its contents. This presentation is not intended for distribution or use by any person or entity that is a citizen or resident of a place, country or other jurisdiction in which such distribution, publication, availability or use may be in conflict with laws or regulations or which would require any registration or licence within such jurisdiction.

